AIMS: This study was conducted to analyze the clinical significance of ASAP1 in epithelial ovarian cancer (EOC). METHODS: A total of 95 patients with EOC were included in the study. The expression profile of ASAP1 in 10 pairs of ovarian cancer and normal ovary tissues were detected by Real-time PCR. The expression level of ASAP1 in 95 paraffin-embedded EOC specimens was measured by immunohistochemistry staining. Statistical analysis was performed to evaluate the clinicopathologic significance of ASAP1. RESULTS: Levels of ASAP1 mRNA were higher in EOC than in normal ovary tissues. Patients with higher ASAP1 expression had shorter overall (P=0.019) and recurrence-free (P=0.030) survival time, whereas those with lower ASAP1 expression survived longer. In addition, high expression of ASAP1 was correlated with poor overall (P=0.044) and recurrence-free (P=0.006) survival in patients with advanced carcinomas. Moreover, statistical analysis displayed a significant correlation in ASAP1 expression with pelvic metastasis (P=0.015). Multivariate analysis revealed that an elevated ASAP1 expression was a significant independent prognostic factor for the overall (P=0.039) and recurrence-free (P=0.028) survival of EOC patients. CONCLUSION: These results indicated that elevated expression of ASAP1 plays an important role in the progression and metastasis of ovarian cancer, and that ASAP1 may be used as a biomarker in predicting patient outcome in EOC patients.
AIMS: This study was conducted to analyze the clinical significance of ASAP1 in epithelial ovarian cancer (EOC). METHODS: A total of 95 patients with EOC were included in the study. The expression profile of ASAP1 in 10 pairs of ovarian cancer and normal ovary tissues were detected by Real-time PCR. The expression level of ASAP1 in 95 paraffin-embedded EOC specimens was measured by immunohistochemistry staining. Statistical analysis was performed to evaluate the clinicopathologic significance of ASAP1. RESULTS: Levels of ASAP1 mRNA were higher in EOC than in normal ovary tissues. Patients with higher ASAP1 expression had shorter overall (P=0.019) and recurrence-free (P=0.030) survival time, whereas those with lower ASAP1 expression survived longer. In addition, high expression of ASAP1 was correlated with poor overall (P=0.044) and recurrence-free (P=0.006) survival in patients with advanced carcinomas. Moreover, statistical analysis displayed a significant correlation in ASAP1 expression with pelvic metastasis (P=0.015). Multivariate analysis revealed that an elevated ASAP1 expression was a significant independent prognostic factor for the overall (P=0.039) and recurrence-free (P=0.028) survival of EOC patients. CONCLUSION: These results indicated that elevated expression of ASAP1 plays an important role in the progression and metastasis of ovarian cancer, and that ASAP1 may be used as a biomarker in predicting patient outcome in EOC patients.
Authors: Katarzyna Kowanetz; Koraljka Husnjak; Daniela Höller; Marcin Kowanetz; Philippe Soubeyran; Dianne Hirsch; Mirko H H Schmidt; Kresimir Pavelic; Pietro De Camilli; Paul A Randazzo; Ivan Dikic Journal: Mol Biol Cell Date: 2004-04-16 Impact factor: 4.138
Authors: Craig Furman; Sarah M Short; Romesh R Subramanian; Bruce R Zetter; Thomas M Roberts Journal: J Biol Chem Date: 2001-12-31 Impact factor: 5.157
Authors: Pei-Wen Chen; Neil Billington; Ben Y Maron; Jeffrey A Sload; Krishna Chinthalapudi; Sarah M Heissler Journal: J Biol Chem Date: 2020-05-22 Impact factor: 5.157
Authors: Neeladri Sekhar Roy; Xiaoying Jian; Olivier Soubias; Peng Zhai; Jessica R Hall; Jessica N Dagher; Nathan P Coussens; Lisa M Jenkins; Ruibai Luo; Itoro O Akpan; Matthew D Hall; R Andrew Byrd; Marielle E Yohe; Paul A Randazzo Journal: J Biol Chem Date: 2019-10-06 Impact factor: 5.157
Authors: Ayse L Mindikoglu; Mustafa M Abdulsada; Antrix Jain; Jong Min Choi; Prasun K Jalal; Sridevi Devaraj; Melissa P Mezzari; Joseph F Petrosino; Antone R Opekun; Sung Yun Jung Journal: J Proteomics Date: 2020-01-09 Impact factor: 4.044